Table 1. EC50 values of JFH1/5ACon1 and its derivatives with resistance-associated NS5A mutations to DCV and LDV.
| Strain (JFH1/5ACon1-) | DCV |
LDV |
||
|---|---|---|---|---|
| EC50 (pM) (95% CI) | Fold Resistance | EC50 (pM) (95% CI) | Fold Resistance | |
| wt | 7.65 (5.61–10.4) | 1.00 | 0.651 (0.560–0.757) | 1.00 |
| L31M | 29.8 (15.1–44.7) | 3.90 | 8.01 (6.03–9.96) | 12.3 |
| L31V | 207 (81.1–333) | 27.1 | 320 (199–441) | 491 |
| L31I | 12.6 (5.61–19.7) | 1.65 | 35.4 (24.3–46.4) | 54.4 |
| Y93H | 566 (347–789) | 74.0 | 3740 (2690–4800) | 5750 |
| L31M/Y93H | 102000 (52900–151000) | 13300 | 258000 (189000–326000) | 396000 |
| L31V/Y93H | 327000 (173000–480000) | 42700 | 353000 (244000–462000) | 542000 |
| L31I/Y93H | 27800 (13300–42200) | 3640 | 156000 (133000–180000) | 240000 |
DCV; Daclatasvir, LDV; Ledipasvir, EC50; effective concentrations required to inhibit 50% of intracellular core protein level, CI; confidence interval.